
    
      The primary objective of this study is to monitor adult subjects, who as participants of a
      clinical trial, received T cells modified by a lentiviral vector encoding a chimeric antigen
      receptor specific for EGFRvIII, for adverse events that may be associated with lentiviral
      vector gene transfer such as insertional oncogenesis.
    
  